Colfax International has introduced the latest generation of ClusterEdge, its ready-to-go high-performance computing (HPC) cluster, which is based on the Intel Xeon processor E5 product family and certified Intel Cluster Ready
Colfax International has launched a low-cost 10 Gigabit Ethernet Value Bundle, which includes a 10GigE Fujitsu switch, Mellanox ConnectX-2 EN adapter cards and Mellanox copper cables
Colfax International has launched server solutions featuring eight-core Intel Xeon processors 7500 series
Colfax International has launched new server and workstation solutions featuring the eight- and twelve-core AMD Opteron 6100 Series processors
Colfax International, a provider of hardware and software for high-performance computing, has added Blade Network Technologies' 1-10 Gigabit Ethernet RackSwitch product family to its product portfolio
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
